MA
AUTL

MYDA Advisors’s Autolus Therapeutics AUTL Stock Holding History

MYDA Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,000
Closed -$214K – 86
2022
Q3 		$214K Hold
100,000
– – 0.1% 116
2022
Q2 		$283K Sell
100,000
-15,000
-13% -$45.6K 0.08% 146
2022
Q1 		$480K Sell
115,000
-10,000
-8% -$42.1K 0.19% 118
2021
Q4 		$649K Sell
125,000
-46,953
-27% -$282K 0.17% 140
2021
Q3 		$1.13M Buy
171,953
+86,953
+102% +$549K 0.32% 82
2021
Q2 		$564K Buy
+85,000
New +$528K 0.14% 173

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

MYDA Advisors's AUTL Position: Q4 2022 in Review

MYDA Advisors sold out of Autolus Therapeutics (AUTL) in Q4 2022, closing a stake of 100,000 shares — an estimated $214K sold.

MYDA Advisors first reported a position in AUTL in Q2 2021 and held it in 6 quarters. The position peaked at $1.13M in Q3 2021. 71 funds tracked by Wall St. Rank hold AUTL as of Q4 2022.

  • MYDA Advisors reported no remaining Autolus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • MYDA Advisors sold 100,000 Autolus Therapeutics shares in Q4 2022, an estimated $214K.
  • MYDA Advisors first reported a position in Autolus Therapeutics in Q2 2021 and held it in 6 quarters.
  • MYDA Advisors's Autolus Therapeutics position peaked at $1.13M in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2022.

Based on MYDA Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.